References
- Fit KE, Williams PC. Use of histamine2-antagonists for the treatment of verruca vulgaris. Ann Pharmacother 2007;41:1222–1226.
- Campoli-Richards DM, Clissold SP. Famotidine. Pharmacodynamic and pharmacokinetic properties and a preliminary review of its therapeutic use in peptic ulcer disease and Zollinger-Ellison syndrome. Drugs 1986;32:197–221.
- Howden CW, Tytgat GN. The tolerability and safety profile of famotidine. Clin Ther 1996;18:36–54; discussion 35.
- Stubbs WA, Delitala G, Besser GM, Edwards CR, Labrooy S, Taylor R et al. The endocrine and metabolic effects of cimetidine. Clin Endocrinol (Oxf) 1983;18:167–178.
- Verdy M, Bolte E, Verdy I. Cimetidine and glucose tolerance (oral and intravenous). Int J Clin Pharmacol Ther Toxicol 1983;21:487–488.
- Gentile S, Marmo R, Costume A, Orlando C, D’Alessandro R, De Bellis G et al. The role of ranitidine infusion on glucose, insulin and C-peptide serum levels induced by oral glucose tolerance test in healthy subjects. Acta Diabetol Lat 1986;23:165–170.
- Scarpignato C, Tirelli F, Starcich R, Bertaccini G. Effect of acute and chronic cimetidine administration on glucose tolerance and insulin secretion in man. Horm Res 1981;15:228–236.
- Das PK, Mostofa M, Hasan Q, Shil GC, Islam MR. Effects of ranitidine, famotidine and omeprazole on some haematobiochemical parameters in mice. J Anim Vet Adv 2003 2:321–326.
- Taha MO, Bustanji Y, Al-Ghussein MA, Mohammad M, Zalloum H, Al-Masri IM et al. Pharmacophore modeling, quantitative structure-activity relationship analysis, and in silico screening reveal potent glycogen synthase kinase-3beta inhibitory activities for cimetidine, hydroxychloroquine, and gemifloxacin. J Med Chem 2008;51:2062–2077.
- Støa-Birketvedt G, Paus PN, Ganss R, Ingebretsen OC, Florholmen J. Cimetidine reduces weight and improves metabolic control in overweight patients with type 2 diabetes. Int J Obes Relat Metab Disord 1998;22:1041–1045.
- Bhat R, Xue Y, Berg S, Hellberg S, Ormö M, Nilsson Y et al. Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J Biol Chem 2003;278:45937–45945.
- OMEGA VUM, OpenEye Scientific Software Inc., Santa Fe, New Mexico, Jul., 2006
- FRED VUM, 2006. OpenEye Scientific Software, (www.eyesopen.com), USA.
- Bustanji Y, Taha MO, Almasri IM, Al-Ghussein MA, Mohammad MK, Alkhatib HS. Inhibition of glycogen synthase kinase by curcumin: Investigation by simulated molecular docking and subsequent in vitro/in vivoevaluation. J Enzyme Inhib Med Chem 2009;24:771–778.
- Mohammad MK, Al-Masri IM, Taha MO, Al-Ghussein MA, Alkhatib HS, Najjar S et al. Olanzapine inhibits glycogen synthase kinase-3beta: an investigation by docking simulation and experimental validation. Eur J Pharmacol 2008;584:185–191.
- Martinez A, Alonso M, Castro A, Pérez C, Moreno FJ. First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer’s disease. J Med Chem 2002;45:1292–1299.
- Carroll NV, Longley RW, Roe JH. The determination of glycogen in liver and muscle by use of anthrone reagent. J Biol Chem 1956;220:583–593.
- Carbohydrate biosynthesis. In: Lehninger principles of biochemistry. 3rd ed. New York: Worth Publishers; 1999. p 735–739.